Engineering a normally responsive bioartificial pancreas based on glucose-hypersensitive cells.
An implantable bioartificial pancreas is promising for diabetes treatment; transformed cells may allow the fabrication of these tissue constructs at a medically relevant scale. However, transformed cells are generally glucose hypersensitive, i.e. insulin secretion is near maximal at much lower than physiological glucose levels. The development of a normally responsive construct based on hypersensitive cells was examined. Two systems of immobilized cells and glucose-consuming enzyme were considered: cells surrounded by the enzyme, and cells coimmobilized with the enzyme. Model simulations showed that, with properly chosen parameter values, the first system can mimic the response of normal islets.
Tziampazis
E
E
School of Chemical Engineering, Georgia Institute of Technology, Atlanta 30332-0100, USA.
Sambanis
A
A
D001786:Blood Glucose / Q000032:analysis; D002461:Cell Line, Transformed / Q000637:transplantation*; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism / Q000628:therapy*; D004337:Drug Carriers; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006019:Glycolysis; D006801:Humans; D007332:Insulin Infusion Systems / Q000592:standards*; D007340:Insulinoma; D009374:Neoplasms, Experimental; D010190:Pancreatic Neoplasms
D001786:Blood Glucose; D004337:Drug Carriers